ASCO Annual Meeting | Conference

Pemetrexed Maintenance Improves Progression-Free Survival in Patients With NSCLC

June 6th 2011

Continuation maintenance with pemetrexed (Alimta) improves progression-free survival in patients with advanced nonsquamous non–small cell lung cancer

Dr. Wolchok Describes the Immunotherapy Ipilimumab

June 6th 2011

Dr. Wolchok from Memorial Sloan-Kettering Cancer Center Describes the Immunotherapy Ipilimumab

Dr. Kris on the Use of Genetic Testing in Lung Cancer

June 6th 2011

Dr. Kris From Memorial Sloan-Kettering Cancer Center on the Use of Genetic Testing in Lung Cancer

MEK and BRAF Therapy Combo Promising for Advanced Melanoma

June 5th 2011

The combination of the MEK inhibitor GSK212 and the oral BRAF inhibitor GSK436 resulted in anti-tumor activity in patients with advanced melanoma

Dr. Virgo on Survivorship Care Training & Policies

June 5th 2011

Dr. Katherine Virgo from the American Cancer Society Discusses Survivorship Care Training & Policies

Dr. Hoos on the Patients That Respond to Ipilimumab

June 5th 2011

Dr. Axel Hoos from Bristol Myers-Squib on the Patients That Respond to Ipilimumab

Dr. Chapman Describes the Side Effects of Vemurafenib

June 5th 2011

Dr. Paul Chapman from Memorial Sloan-Kettering Cancer Center Describes the Side Effects of Vemurafenib

Dr. Tsimberidou Discusses Improving Care

June 5th 2011

Apostolia M. Tsimberidou, MD, PhD, from MD Anderson Cancer Center discusses improving cancer care.

Dr. Cella on Patient Assessment Reference Scores

June 5th 2011

Dr. Cella from Northwestern University Feinberg School of Medicine on Patient Assessment Reference Scores

Genetic Testing Delivers Personalized Lung Cancer Therapy

June 5th 2011

Taking a page from breast cancer treatment, clinicians managing lung cancer patients can now detect mutations that drive the development of lung cancer

NKTR-102 Shows Promise in Phase II Trial

June 5th 2011

Metastatic breast cancer patients with demonstrated disease progression after taxane therapy face an uphill battle in fighting their disease.

Circulating Tumor Cells Show Promise as Surrogate for Survival in Prostate Cancer Trials

June 5th 2011

Prostate cancer research lacks surrogate biomarkers for survival that could hasten the study and approval of new medications.

Regional Radiation Therapy Improves Outcomes in Early Breast Cancer

June 5th 2011

Radiation therapy directed to the regional lymph nodes of women with early-stage breast cancer reduced distant disease recurrence

Amonafide Plus Cytarabine Fails To Meet Primary Endpoint

June 4th 2011

Amonafide+Cytarabine may not be effective for secondary acute myeloid leukemia, according to ACCEDE trial data

High-Dose Methotrexate Better for ALL

June 4th 2011

High doses of methotrexate increases EFS for children and young adults

Molecular Profiling Boosts Targeted Therapies in Phase I Trial

June 4th 2011

Matching patients with targeted therapies based on molecular profile results in superior clinical outcomes

Dr. Joensuu on the Imatinib for High-Risk GIST Trial

June 4th 2011

Dr. Heikki Joensuu from the Helsinki University Central Hospital Summarizes the Imatinib for High-Risk high-risk gastrointestinal stromal tumors (GIST) Trial

Tim Turnham Discusses Melanoma Treatment Advances

June 4th 2011

Tim Turnham the Executive Director of the Melanoma Research Foundation Discusses Melanoma Treatment Advances

Investors Taking Stock of Key ASCO Abstracts

May 19th 2011

Oncology specialists, biopharmaceutical analysts and investors all await the latest research news from the upcoming ASCO annual meeting

Genetic Analysis Yields Biomarker for Neuropathy

May 18th 2011

A genetic analysis resulted in the discovery of the first predictive biomarker for taxane-induced peripheral neuropathy